As insurers limited protection of behavioral suffering therapy, biopharmaceutical producers sensed a chance. Pharmaceutical innovation propagated prolonged-launch formulations, transdermal patches, nasal sprays, and oral dissolving strips. Health care product producers drove a proliferation of novel pain-modulating implants. By 2000, Long-term suff